Omega Therapeutics, Inc.
OMGA · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.11 | -0.06 | -0.06 | -0.41 |
| FCF Yield | -58.05% | -36.54% | -10.91% | -3.65% |
| EV / EBITDA | -2.38 | -2.31 | -5.80 | -27.42 |
| Quality | ||||
| ROIC | -51.99% | -78.75% | -30.22% | -122.50% |
| Gross Margin | -2,028.93% | -150.36% | -863.19% | 0.00% |
| Cash Conversion Ratio | 0.94 | 0.96 | 0.84 | 0.89 |
| Growth | ||||
| Revenue 3-Year CAGR | 178.00% | – | – | -100.00% |
| Free Cash Flow Growth | 5.52% | -69.10% | -111.43% | -68.69% |
| Safety | ||||
| Net Debt / EBITDA | -0.64 | 0.49 | 2.58 | 0.41 |
| Interest Coverage | 0.00 | 0.00 | -72.56 | -36.87 |
| Efficiency | ||||
| Inventory Turnover | 217.39 | 0.13 | -5.25 | 0.00 |
| Cash Conversion Cycle | 816.84 | 2,992.12 | 696.12 | -338.56 |